Japan, with its rapidly aging population, is expected to have more than 5 million patients with dementia by 2030. Alzheimer’s ...

Eli Lilly said on Tuesday Japan's health ministry has approved donanemab, its drug for Alzheimer's disease, providing ...

Eli Lilly’s (NYSE:LLY) treatment for early Alzheimer's disease has been approved for use in Japan. Kisunla (donanemab-azbt), ...

Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for ...

The Ministry of Health, Labour and Welfare Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks ...

Amgen said on Tuesday that its drug helped improve daily activities including chewing and swallowing in patients suffering ...

An analysis of Eli Lilly's stock reveals high premium, overvaluation concerns and a low dividend yield. LLY is rated hold due ...

Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...

Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their ...

Eli Lilly has received approval in Japan for Kisunla (donanemab-azbt) to treat early symptomatic Alzheimer's disease.